newsfilter
← Latest News
Business Wire·

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

Strong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflecting 54% year-over-year growth ZEVTERA (ceftobiprole medocaril sodium, for injection)